Verastem (VSTM) Competitors $7.46 +0.34 (+4.71%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. CLDX, INVA, NVAX, OPK, GERN, MYGN, ZBIO, RIGL, XOMA, and VNDAShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Verastem vs. Celldex Therapeutics Innoviva Novavax OPKO Health Geron Myriad Genetics Zenas Biopharma Rigel Pharmaceuticals XOMA Vanda Pharmaceuticals Verastem (NASDAQ:VSTM) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking. Is VSTM or CLDX more profitable? Verastem has a net margin of 0.00% compared to Celldex Therapeutics' net margin of -1,544.32%. Celldex Therapeutics' return on equity of -19.75% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -332.73% -73.97% Celldex Therapeutics -1,544.32%-19.75%-18.86% Does the MarketBeat Community believe in VSTM or CLDX? Celldex Therapeutics received 5 more outperform votes than Verastem when rated by MarketBeat users. Likewise, 75.24% of users gave Celldex Therapeutics an outperform vote while only 65.33% of users gave Verastem an outperform vote. CompanyUnderperformOutperformVerastemOutperform Votes61865.33% Underperform Votes32834.67% Celldex TherapeuticsOutperform Votes62375.24% Underperform Votes20524.76% Does the media prefer VSTM or CLDX? In the previous week, Verastem had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Verastem and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.34 beat Verastem's score of 0.55 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in VSTM or CLDX? 88.4% of Verastem shares are owned by institutional investors. 2.2% of Verastem shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, VSTM or CLDX? Verastem has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$10M36.94-$87.37M-$3.50-2.05Celldex Therapeutics$7.02M183.74-$141.43M-$2.45-7.93 Which has more risk and volatility, VSTM or CLDX? Verastem has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Do analysts recommend VSTM or CLDX? Verastem presently has a consensus target price of $13.89, suggesting a potential upside of 93.57%. Celldex Therapeutics has a consensus target price of $54.33, suggesting a potential upside of 179.64%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 SummaryCelldex Therapeutics beats Verastem on 11 of the 19 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$369.44M$6.51B$5.35B$7.51BDividend YieldN/A3.21%5.44%4.34%P/E Ratio-2.257.0021.9718.05Price / Sales36.94260.09396.62104.31Price / CashN/A65.6738.2034.62Price / Book3.166.346.734.14Net Income-$87.37M$142.49M$3.21B$247.59M7 Day Performance44.66%11.74%6.42%6.27%1 Month Performance7.89%-6.28%-5.85%-3.48%1 Year Performance-25.34%-1.93%15.28%2.86% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem2.7454 of 5 stars$7.46+4.7%$13.89+86.3%-25.3%$385.15M$10M-2.3450News CoverageGap UpCLDXCelldex Therapeutics2.7193 of 5 stars$18.94+3.5%$54.33+186.9%-48.6%$1.26B$7.02M-7.37150News CoverageINVAInnoviva4.1704 of 5 stars$18.28+0.1%$55.00+200.9%+21.1%$1.15B$358.71M26.49100Analyst DowngradePositive NewsNVAXNovavax3.645 of 5 stars$6.01+0.2%$18.00+199.5%+78.6%$966.67M$682.16M-2.661,990News CoverageGap UpOPKOPKO Health4.0398 of 5 stars$1.37-3.5%$2.75+100.7%+17.2%$920.02M$713.14M-7.214,200Upcoming EarningsPositive NewsGERNGeron3.7869 of 5 stars$1.35+6.3%$5.75+325.9%-60.3%$859.83M$76.99M-4.2270Analyst RevisionGap UpMYGNMyriad Genetics3.8585 of 5 stars$7.40-3.1%$20.61+178.5%-60.8%$682.07M$837.60M-5.692,600Analyst RevisionGap UpHigh Trading VolumeZBIOZenas BiopharmaN/A$9.75+9.3%$40.00+310.3%N/A$407.54M$5M-2.75N/ANews CoverageGap UpRIGLRigel Pharmaceuticals2.7297 of 5 stars$16.93+0.5%$36.80+117.4%+59.3%$302.49M$179.28M120.94160Positive NewsXOMAXOMA4.2803 of 5 stars$22.09+4.3%$59.67+170.1%-10.5%$264.04M$10.22M-6.3510Gap UpVNDAVanda Pharmaceuticals4.0073 of 5 stars$4.29-0.9%$16.50+284.6%-6.5%$250.18M$198.77M-13.41290News Coverage Related Companies and Tools Related Companies Celldex Therapeutics Alternatives Innoviva Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Myriad Genetics Alternatives Zenas Biopharma Alternatives Rigel Pharmaceuticals Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VSTM Stock Free VSTM Stock Alerts